Literature DB >> 23303273

When choosing statin therapy: the case for generics.

Jonas B Green1, Joseph S Ross, Cynthia A Jackevicius, Nilay D Shah, Harlan M Krumholz.   

Abstract

The development of "Top 5" lists across specialties and at regular intervals can help to remind physicians that optimal care is often possible at a lower cost. For purposes of cardiovascular risk reduction, generic statins, or their brand equivalents if priced similarly, remain the appropriate choice for dyslipidemic patients initiating statin therapy. In this article, we review the evidence supporting the choice of generic statins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303273     DOI: 10.1001/jamainternmed.2013.1529

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  3 in total

1.  Health care for patients with serious mental illness: family medicine's role.

Authors:  Nancy E Morden; Lisa A Mistler; William B Weeks; Stephen J Bartels
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

2.  Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.

Authors:  Walid F Gellad; Julie M Donohue; Xinhua Zhao; Maria K Mor; Carolyn T Thorpe; Jeremy Smith; Chester B Good; Michael J Fine; Nancy E Morden
Journal:  Ann Intern Med       Date:  2013-07-16       Impact factor: 25.391

3.  Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes.

Authors:  Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.